The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Arcturus has made progress in cost-cutting and focusing on CF and OTC deficiency. Click here to find out the factors that ...

Professor Hirohide Saito (Department of Life Science Frontiers at CiRA / The University of Tokyo) and Assistant Professor ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

The inaccurate rumours refer to a study looking at excess deaths during the pandemic in the German city of Frankfurt am Main.

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...